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Inhibition of myo-inositol transport causes acute renal failure with
selective medullary injury in the rat. Myo-inositol is a major compatible
osmolyte in the renal medulla that is accumulated under hypertonic
conditions via the Na1/myo-inositol cotransporter (SMIT). We have
recently reported that SMIT is predominantly present in the thick
ascending limb of Henle (TAL) and is strongly induced by acute NaCl
loading, suggesting an important role of myo-inositol in this nephron
segment. In the present study, we sought to examine in vivo effects of
inhibition of myo-inositol transport using a transport inhibitor, 2-O,
C-methylene-myo-inositol (MMI). Intraperitoneal injection of MMI
caused acute renal failure in the rats. Serum creatinine and urea nitrogen
were significantly increased 12 hours after MMI injection. Morphologic
study revealed that the tubular cells were extensively injured in the outer
medulla. A considerable number of the tubular cells were injured in the
cortex as well. Immunohistochemical study for Tamm-Horsfall protein
(THP), which was used for identification of the TAL cells, showed that
THP-positive cells were predominantly injured. The tubular injury appar-
ently appeared to worsen when high concentration of NaCl was injected
with MMI. Administration of myo-inositol prevented acute renal failure
and improved the tubular injury after MMI injection. Furthermore,
supplementation of betaine, another osmolyte in the TAL cells, partially
prevented the toxic effects of MMI. These results suggest that myo-inositol
play a crucial role in the TAL regarding osmoregulation of the cells.
Myo-inositol has been identified as one of major osmolytes in
various tissues and types of cells [1–3]. Madin-Darby canine
kidney (MDCK) cells accumulate myo-inositol through Na1-
coupled transporter when cultured in a hypertonic medium. A
cDNA encoding Na1/myo-inositol cotransporter (SMIT) was
isolated from MDCK cells [4]. The increase in SMIT transporter
activity in response to hypertonicity is preceded by an increase in
transcription of SMIT and in the abundance of SMIT mRNA [5].
These results of cultured cells suggest that transcription is a key
step in regulation of myo-inositol transport by hypertonicity.
Animal studies have shown that myo-inositol is the only os-
molyte found in substantial amounts in the cortex and the outer
medulla in addition to the inner medulla of the kidney [6]. Our
previous report demonstrated that SMIT mRNA abundance was
highest in the outer medulla, and a small but significant amount of
SMIT mRNA was present in the cortex [7]. There is some
evidence that myo-inositol in the outer medulla is mainly present
in the thick ascending limb of Henle (TAL). Microdissection
studies revealed that TAL and medullary collecting duct cells
contained the highest concentration of myo-inositol in the
nephron [8]. We demonstrated that SMIT mRNA was predomi-
nantly present in the TAL as well as inner medullary collecting
ducts (IMCD) using an in situ hybridization technique [9].
Other major osmolytes in the kidney medulla are sorbitol,
betaine and glycerophosphorylcholine (GPC) [10]. When extra-
cellular osmolarity increases, sorbitol is synthesized from glucose
by aldose reductase (AR) and betaine is taken up into cells via
betaine g-amino-n-butyric acid cotransporter (BGT-1). Aldose
reductase and BGT-1 are regulated by extracellular osmolarity at
the level of transcription [11, 12], and we have recently reported
the localization of the expression of these osmoregulatory genes
[13]. Aldose reductase mRNA was localized in the thin limbs of
Henle and the IMCD, which paralleled the inner medullary
osmolarity profile. In contrast, BGT-1 mRNA signals were
present in the medullary portion of thick ascending limbs (mTAL)
and the IMCD. These results indicate that osmolyte transport-
er(s) highly express in the TAL segment against the corticomed-
ullary osmotic gradient. Our main interest in this study is the role
of the osmolyte transporter in this nephron segment.
One of the useful methods to investigate the role of transport-
ers is to see the effects of inhibition of the transport. We have
recently shown that 2-O,C-methylene-myo-inositol (MMI) be-
haves as a competitive inhibitor of myo-inositol transport in
MDCK cells with relatively high inhibition constant (Ki) value
(1.6 mM) [14]. MMI markedly reduced myo-inositol content in
MDCK cells, but MMI itself did not accumulate into the cells.
Colony-forming efficiency apparently decreased in the presence of
MMI when the cells were cultured in a hypertonic medium.
Addition of myo-inositol returned the efficiency to the value
without MMI. Interestingly, addition of betaine also increased the
colony-forming efficiency in the presence of MMI, suggesting that
myo-inositol depletion can be at least partly replaced by betaine.
It is likely that administration of MMI in vivo inhibit myo-
inositol transport by the tubular cells in the kidney. In the present
study, we performed intraperitoneal injection of MMI in rats to
see the effects of myo-inositol depletion on the kidney. We further
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studied whether supplementation of osmolytes (myo-inositol or
betaine) would counteract the toxic effects of MMI.
METHODS
Animals
Male Sprague-Dawley rats, weighing ;200 g, received water
and standard rat chow for several days prior to the experiments.
According to the report by Weinhold et al [15], a minimal lethal
dose of MMI was ;100 mg/kg in rats. In the preliminary
experiments, we injected various amount of MMI. Tubular inju-
ries were minimal under 50 mg/kg. More than 50 mg/kg, the
tubular cells appeared to be damaged in a dose-dependent
manner. So we decided to inject sublethal dose (60 ; 80 mg/kg)
of MMI.
To see the effects of NaCl loading, intraperitoneal injection of
0.5 ml of 3 M NaCl per 100 g body wt was performed simulta-
neously with injection of 60 mg/kg of MMI. To see the effects of
osmolyte supplementation, 800 mg/kg of myo-inositol or betaine
was administered simultaneously with injection of 80 mg/kg of
MMI.
The animals were sacrificed under pentobarbital anesthesia.
After blood samples were taken, kidneys on both sides were
perfused with 4% paraformaldehyde solution and then removed.
Serum creatinine and urea nitrogen were measured by automated
methods (SRL, Tokyo, Japan).
Histological evaluation
Tissues for light microscopy were dehydrated through a graded
ethanol series and embedded in paraffin. Histologic sections (2
mm) of kidneys from both sides were stained with hematoxylin and
eosin (HE).
Histologic sections were processed by an indirect immunoper-
oxidase technique using a commercial kit (Vectastain ABC kit,
Vector Laboratories, Inc., Burlingame, CA, USA) with an anti-
body against human Tamm-Horsfall protein (THP) (Chemicon
International, Inc., CA, USA). Biotinylated donkey anti-sheep
IgG (Chemicon International, Inc., CA, USA) was used as a
second antibody.
In situ hybridization
For hybridization of THP mRNA, oligonucleotide probe spe-
cific to THP mRNA [16] (59-GAACAATCAGGGTCAAAG-
TAGCTGAGAGAAACAGCAGCAGCCAGATGC-39) compli-
mentary bases 1907-1954, were synthesized using an Applied
Biosystems DNA synthesizer, then purified using Hitachi high
performance liquid chromatography (ODS column chromatogra-
phy). The probes were labeled at the 39 end using [a-35S] ATP
(1000-1500 Ci/mmol; NEN).
The kidneys after the perfusion of paraformaldehyde were
placed in a solution of 4% paraformaldehyde for two hours and
30% sucrose overnight. Cryostat sections (5 mm) were mounted
on siliconized slides. The slides were fixed in 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.2) for 30 minutes. After
rinsing three times (5 min each) in 4 3 SSC (pH 7.2; NaCl 35
g/liter, sodium citrate 17.6 g/liter), they were dehydrated in
increasing concentrations of ethanol. They were subsequently
defatted with chloroform for seven minutes, and immersed in
100% ethanol (twice for 3 min each time) before being subjected
to hybridization.
In situ hybridization using THP oligonucleotide probe was
performed essential as reported previously [17]. The probe con-
centration was 1 3 106 cpm/200 ml per slide. The specificity of
oligonucleotide probes were verified by control hybridization
experiments using RNase treatment (10 mg/ml) prior to hybrid-
ization, or adding the unlabeled probe in excess (100-fold) to the
hybridization buffer. No significant signals above background
were detected in sections processed after RNase treatment or with
a mixture of labeled and excess unlabeled probes.
Fig. 1. Intraperitoneal injection of 80 mg/kg of MMI was performed to 9
rats. Three rats received 800 mg/kg of myo-inositol (MMI 1 myo-inositol;
E) simultaneously with MMI and other three rats were given the same
amount of betaine (MMI 1 betaine; e). The rest of the rats did not
receive the osmolytes (MMI only; ). The rats injected MMI alone died
within 48 hours. Myo-inositol supplementation completely rescued the rats
and betaine increased the survival rate.
Table 1. Serum creatinine and urea nitrogen following administration
of 2-O,C-methylene-myo-inositol (MMI)
Time after
injection N Creatinine Urea nitrogen
0 hours 3 0.13 6 0.06 12.2 6 0.9
8 hours 3 0.23 6 0.23 10.3 6 4.1
12 hours 3 1.43 6 0.35a 59.4 6 3.9a
12 hours 1 MI 3 0.13 6 0.06c 12.0 6 2.3c
12 hours 1 Bet 3 0.57 6 0.15bc 26.2 6 6.6ac
24 hours 3 3.07 6 0.06a 109.0 6 4.6a
24 hours 1 MI 3 0.20 6 0.10d 10.5 6 3.5d
24 hours 1 Bet 3 2.17 6 0.68ae 93.0 6 9.5ae
Intraperitoneal injection of 80 mg/kg of MMI was performed to male
Sprague-Dawley rats. After 8, 12 or 24 hours, blood samples were taken
and the rats were sacrificed. Some rats received myo-inositol (1 MI) or
betaine (1 Bet) administration simultaneously with MMI injection and
sacrificed after 12 or 24 hours. All experiments were performed more than
twice with similar results.
a P , 0.001 and b P , 0.05 vs. 0 hours
c P , 0.001 vs. 12 hours
d P , 0.001 and e P , 0.01 vs. 24 hours
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Fig. 2. Longitudinal section of whole kidney
after MMI injection. The rats received 80 mg/
kg of MMI died within 48 hours. When the
animals died, the kidneys were removed and
bisected longitudinally. There were clearly
demarked rings in the juxtamedullary region
(arrow).
Fig. 3. Hematoxylin and eosin staining of the kidneys from the control rat (A, C, E) and the rat received 80 mg/kg of MMI (B, D, F). The rats were
sacrificed 12 hours after MMI injection. A and B. Cortex with glomerulus (3400). C and D. Outer medulla (3400). E and F. Inner medulla (3 400).
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RESULTS
As shown in Table 1, serum creatinine and urea nitrogen were
significantly increased 12 hours after administration of 80 mg/kg
of MMI. These values continued to elevate for 24 hours. The rats
died within 48 hours (Fig. 1). When the animals died, hemisection
of the kidney showed clearly demarked rings in the juxtamedullary
region (Fig. 2). Macroscopic examination of the kidneys suggested
that the white rings were due to necrosis and shrinkage of the
tissue in the outer medulla. No significant changes were observed
in other organs including brain, eye and ear. To determine which
kind of cells were basically damaged in the kidney, histological
examination was performed in the early phase (5 ; 12 hr) after
MMI administration.
Figure 3 shows the histological change in the kidney 12 hours
after administration of 80 mg/kg of MMI. In the outer medulla,
extensive vacuolar changes were noted in the tubular cells (Fig.
3D). A part of the tubular cells were also damaged in the cortex,
although no remarkable change was observed in the glomerulus
(Fig. 3B). In contrast, the cells in the inner medulla were little
affected and most of the cells looked intact (Fig. 3F). Thus, MMI
caused degeneration and necrosis of the tubular cells predomi-
nantly in the outer medulla.
Since SMIT is localized to the TAL and the collecting duct cells
[9], the damaged cells are presumed to include one of them or
both. To determine which part of the nephron was primarily
injured by MMI, we performed immunohistochemical study using
anti-THP antibody in the early stage after MMI administration. It
has been established that THP protein [18] as well as its mRNA
[19] is localized to the TAL and is often used for identification of
the TAL cells. Figure 4 shows HE staining and THP staining on
consecutive sections of the outer medulla five hours after MMI
administration. The HE staining showed that some of the tubular
cells were degenerated but the others looked intact or less injured
(Fig. 4A). Tamm-Horsfall protein staining on the consecutive
section clearly showed that severe injured cells were THP-positive
(Fig. 4B). This suggested that extensive tubular degeneration
initially occurred in the TAL cells, whereas other types of cells
were damaged less or were spared.
Figures 5 and 6 showed THP staining 12 hours after MMI
injection. When the cells were damaged by MMI, the intensity of
the staining tended to be reduced. The intensity of THP staining
seemed to be proportional to the severity of the damages. Sixty
mg/kg of MMI decreased the THP staining (Fig. 5B) compared
with control kidney (Fig. 5A). Although the number of stained
cells was comparable to the control, the intensity of the staining
seemed to be reduced. Negative-staining cells were also affected
but appeared to be less injured. When 80 mg/kg of MMI was
injected, most of cells in the outer medulla were injured 12 hours
after the injection. The THP staining markedly decreased al-
though THP-positive cells could not be distinguished well (Fig.
6B). Either number of the stained cells or the intensity of the
staining appeared to be reduced.
Fig. 4. Hematoxylin and eosin staining (A) and immunohistochemical staining of THP (B) on consecutive sections in the outer medulla of the kidney
from the rats received 80 mg/kg of MMI. The rats were sacrificed five hours after MMI injection. The arrows and asterisks show the corresponding
tubules that were stained by THP.
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To see the effects of NaCl loading on tubular damage by MMI
administration, high concentration of NaCl was simultaneously
injected with MMI. Comparing to the kidney in the rats with MMI
alone (Fig. 5B), tubular cells looked severely damaged (Fig. 5C).
There were scattered necrotic cells in the outer medulla and THP
staining was further decreased. Thus, acute NaCl loading ap-
peared to worsen MMI toxicity.
If the toxic effects of MMI are due to deficiency of myo-inositol,
administration of myo-inositol would prevent the tubular injury.
To clarify this issue, myo-inositol was injected simultaneously with
MMI at a concentration ten times the value of MMI. In prelim-
inary experiments, we administered various amounts of myo-
inositol. The beneficial effects of myo-inositol on MMI toxicity
appeared to be proportional to the amount used (data not shown).
Eight hundred mg/kg of myo-inositol completely prevented acute
renal failure caused by 80 mg/kg of MMI. Serum creatinine and
urea nitrogen did not change at 12 or 24 hours after MMI
injection (Table 1). All of the rats survived at least until 72 hours
(Fig. 1). At 72 hours after injection of MMI plus myo-inositol,
serum creatinine was 0.23 6 0.06 mg/dl and serum urea nitrogen
was 29.0 6 3.8 mg/dl.
Myo-inositol supplementation dramatically improved the tubu-
lar damage (Fig. 6C). There was only a little difference in the THP
staining between the control rat (Fig. 6A) and the rat with
myo-inositol supplementation. We also performed in situ hybrid-
ization for THP mRNA. MMI injection markedly decreased the
signals for THP mRNA (Fig. 7B), which also suggested the severe
injury of the TAL segment. Myo-inositol supplementation (Fig.
7C) restored the signals as the control (Fig. 7A). These results
suggest that the damage of the tubular cells by MMI is not due to
non-specific toxicity of the drug but is due to myo-inositol
deficiency.
Our recent studies suggested that both myo-inositol and betaine
function as osmolytes in the TAL cells [9] [13]. We speculated that
betaine might be able to replace myo-inositol depletion in vivo
after administration of MMI. Supplementation of betaine (800
mg/kg) significantly decreased serum creatinine and urea nitrogen
compared to MMI administration alone (Table 1). Betaine in-
creased survival rate of the rats with injection of MMI (Fig. 1).
Histological changes in the tubular cells were improved and the
THP positive cells were apparently increased (Fig. 6D). In situ
hybridization for THP mRNA revealed that the signals for THP
mRNA were increased by betaine supplementation (Fig. 7D).
These results suggest that myo-inositol depletion can be at least
partly replaced by betaine in the TAL cells, as suggested in the
study of cultured cells [14].
DISCUSSION
Our results indicate that administration of inhibitor for myo-
inositol transport induced acute renal failure in the rats. Histo-
logical and immunohistochemical studies revealed that tubular
degeneration and necrosis occurred predominantly in the outer
medulla. In the early stage after MMI injection, it was apparent
that THP-positive cells were predominantly injured (Fig. 4). This
indicates that primary target of MMI toxicity is the TAL cells.
THP-negative cells in the outer medulla were also damaged
thereafter (Figs. 5 and 6). The damaged TAL cells might have
some deleterious effects on the other cells in the vicinity.
As shown in the experiments of cultured cells [14], MMI
competitively inhibited myo-inositol transport but did not accu-
mulate into cells. Moreover, supplementation of myo-inositol
prevented MMI toxicity both in cultured cells and in rat kidney.
These results suggest that the cell injury caused by MMI admin-
istration is not due to the non-specific toxicity of MMI but to
specific action on myo-inositol transport. Myo-inositol and its
derivatives play a part in many aspects of cellular regulation,
including membrane structure and signal transduction as well as
osmoregulation. If inhibition of myo-inositol transport affected
membrane structure or signal transduction, every cell would be
damaged. The localized lesion indicates that the injury occurs only
Fig. 5. Immunohistochemical staining of THP in the outer medulla from
the control rat (A) and the rat received 60 mg/kg of MMI (B). Intraperi-
toneal injection of 0.5 ml of 3 M NaCl per 100 g body wt was performed
simultaneously with injection of 60 mg/kg of MMI (C). The rats were
sacrificed 12 hours after the injection.
Kitamura et al: Inhibition of myo-inositol transport150
in the cells which require a large amount of myo-inositol. There is
some evidence that the rate of synthesis of phosphatidylinositol is
already saturated at much lower concentration of myo-inositol
[20] compared with the concentration for osmoregulation. We
also found the beneficial effects of betaine, another osmolyte in
the kidney, on MMI toxicity. Although we cannot deny the
possibility that myo-inositol has a special role in the TAL, it is
probable that the damage is due to the failure of osmoregulation.
The localized lesions may be explained by our recent findings
for the localization of expression for osmolyte-related genes.
SMIT mRNA is predominantly present in the TAL and the IMCD
cells [9]. BGT-1 mRNA expresses in the mTAL as well as the
IMCD [13], whereas AR mRNA is localized in the thin limbs of
Henle and the IMCD. Glycerophosphorylcholine is predomi-
nantly present in the inner medulla as well [21]. Because all of
these osmolytes are available to IMCD cells, depletion of myo-
inositol is likely to be replaced by other osmolytes. In contrast,
TAL cells do not accumulate sorbitol or GPC. Since SMIT and
BGT-1 express in the mTAL, the cells in this portion can use
myo-inositol and betaine. Myo-inositol appears to be the only
osmolyte for the cortical portion of TAL (cTAL). When myo-
inositol is depleted, there seems to be no or only one osmolyte
available to replace myo-inositol in this segment. The TAL cells,
thus, seem to be susceptible to myo-inositol deficiency.
The reason why the cells in this segment need a large amount of
the osmolytes has not yet been clarified. SMIT and BGT-1
mRNAs are rapidly increased following NaCl loading and are
down-regulated by furosemide administration in the TAL [9] [13],
suggesting that expression of these transporter mRNAs changes
with the magnitude of NaCl reabsorption of the TAL cells. This
segment is essentially impermeable to water, and the cells reab-
sorb ions without water movement. We assume that the osmolar-
ity close to basolateral plasma membrane of the tubular cells, that
is, peritubular osmolarity [22], is very high throughout the TAL.
The increased reabsorption of NaCl results in the elevation of
peritubular osmolarity, which induces the expression of osmolyte
transporter in this segment. It is possible that in the presence of
MMI the cells cannot accumulate enough myo-inositol so that the
cells may be damaged by the extracellular hypertonicity on the
basolateral surface.
Although we did not measure the local osmolarity in vivo,
beneficial effects of betaine supplementation on the tubular injury
supports this hypothesis. Myo-inositol and betaine are considered
to function as osmolytes in the TAL cells as well as in MDCK
cells. When MDCK cells were cultured in a hypertonic medium,
betaine increased colony-forming efficiency in the presence of
MMI [14]. This suggests that myo-inositol depletion caused by
MMI can be replaced by betaine in MDCK cells. It is likely that
the cells accumulate more betaine instead of myo-inositol. We
speculate that the same things happened to the TAL cells when
Fig. 6. Immunohistochemical staining of THP in the outer medulla from the control rat (A) and the rat with injection of 80 mg/kg of MMI (B). To
see the effects of osmolyte supplementation, 800 mg/kg myo-inositol (C) or betaine (D) was administered simultaneously with injection of 80 mg/kg of
MMI. The rats were sacrificed 12 hours after the injection.
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administered MMI in the rats. SMIT and BGT-1 strongly express
in the TAL cells. Administration of MMI caused myo-inositol
depletion in the rat but the TAL cells utilized betaine instead of
myo-inositol.
Our previous studies have shown that BGT-1 expresses in the
mTAL but not in the cTAL [13]. Since the expression of BGT-1
disappeared abruptly at the junction of outer medulla and cortex,
we speculated the disappearance might be due to change of the
type of cells. If this is true, betaine supplementation would
improve the lesion only in the mTAL. We are not, however,
convinced of this issue. Betaine actually seemed to ameliorate the
lesion in the cortex as well. The tubular cells in the cTAL may be
able to use betaine when myo-inositol is depleted. Alternatively, it
is possible that betaine might be transported into the cells via a
system A amino acid transporter, as shown in the cell line of
fibroblasts.
In the experiments of MDCK cells, we showed that the Ki value
of MMI (1.6 mM) is about ten times the Km value for myo-inositol
[14]. One might question whether the concentration of MMI
really was elevated enough to inhibit myo-inositol uptake in vivo.
We injected 60 ; 80 mg/kg of MMI into the rats. If MMI was
absorbed rapidly and was uniformly distributed in extracellular
fluid, the concentration of MMI would become more than 1.5 mM.
Thus, the MMI seemed to be elevated to the concentration
comparable to the Ki value. It was unexpected that all of the rats
died within 48 hours after MMI injection. To examine whether the
rats would die within a short term by acute renal failure alone, we
performed nephrectomy of both kidneys. Serum creatinine and
urea nitrogen were progressively increased after nephrectomy and
all of the rats died within 36 hours (unpublished observation). It
is possible that MMI might have some toxic effects on other
organs.
Myo-inositol and its transporter were found in various tissues
other than the kidney. We have recently reported that SMIT
mRNA was present in brain, eye and ear [23–25] and was
regulated by NaCl loading in these tissues as in the kidney [26].
We looked into these tissues after MMI injection but no signifi-
cant changes were observed. Myo-inositol may not be essential for
these tissues. Other substances could replace myo-inositol deple-
tion in these tissues as suggested in the IMCD cells. Alternatively,
it is possible that MMI concentration was not elevated enough to
inhibit myo-inositol transport in these organs.
In summary, we examined the effects of inhibition of myo-
inositol transporter in vivo by means of administration of a
transport inhibitor. MMI administration induced acute renal
failure in the rats. Histological and immunohistochemical studies
revealed that the TAL cells were predominantly injured. NaCl
loading apparently worsened the tubular injury caused by MMI.
Supplementation of myo-inositol prevented acute renal failure
and tubular damage. Betaine supplementation ameliorated the
Fig. 7. Dark field photomicrographs demonstrating the pattern of in situ hybridization of 35S-labeled rat THP antisense oligonucleotide probe to a
cryosection of paraformaldehyde-fixed rat kidney (320). (A) Control rat; (B) rat with injection of 80 mg/kg of MMI; (C) rat with injection of 80 mg/kg
of MMI plus 800 mg/kg myo-inositol; (D) rat with injection of 80 mg/kg of MMI plus 800 mg/kg of betaine. The rats were sacrificed 12 hours after the
injection.
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tubular injury, suggesting that myo-inositol depletion can be
replaced by betaine. These results suggest that myo-inositol and
betaine function as osmolyte in the TAL cells and compensate
each other.
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